Cargando…

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint

[Image: see text] Immune checkpoint blockade is one of the most promising strategies of cancer immunotherapy. However, unlike classical targeted therapies, it is currently solely based on expensive monoclonal antibodies, which often inflict immune-related adverse events. Herein, we propose a novel s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Konieczny, Magdalena, Musielak, Bogdan, Kocik, Justyna, Skalniak, Lukasz, Sala, Dominik, Czub, Miroslawa, Magiera-Mularz, Katarzyna, Rodriguez, Ismael, Myrcha, Maja, Stec, Malgorzata, Siedlar, Maciej, Holak, Tad A., Plewka, Jacek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2020
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584369/ https://www.ncbi.nlm.nih.gov/pubmed/32936638 http://dx.doi.org/10.1021/acs.jmedchem.0c01260

Ejemplares similares

CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?
por: Musielak, Bogdan, et al.
Publicado: (2019)

Human and mouse PD-L1: similar molecular structure, but different druggability profiles
por: Magiera-Mularz, Katarzyna, et al.
Publicado: (2020)

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
por: Surmiak, Ewa, et al.
Publicado: (2021)

Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies
por: Rodriguez, Ismael, et al.
Publicado: (2023)

Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
por: Muszak, Damian, et al.
Publicado: (2021)

Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists
por: Butera, Roberto, et al.
Publicado: (2021)

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017)

Competition NMR for Detection of Hit/Lead Inhibitors of Protein–Protein Interactions
por: Musielak, Bogdan, et al.
Publicado: (2020)

Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors
por: Ważyńska, Marta A., et al.
Publicado: (2023)

Exploring the Surface of the Ectodomain of the PD-L1 Immune Checkpoint with Small-Molecule Fragments
por: Kitel, Radoslaw, et al.
Publicado: (2022)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
por: Zyla, Edyta, et al.
Publicado: (2021)

Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction
por: Shaabani, Shabnam, et al.
Publicado: (2022)

Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
por: Skalniak, Lukasz, et al.
Publicado: (2018)

Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
por: Zak, Krzysztof M., et al.
Publicado: (2016)

Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists
por: Kocik, Justyna, et al.
Publicado: (2019)

Development of the Inhibitors That Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles
por: Guzik, Katarzyna, et al.
Publicado: (2019)

Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein
por: Reyes Romero, Atilio, et al.
Publicado: (2022)

Specific Antibody Fragment Ligand Traps Blocking FGF1 Activity
por: Chudzian, Julia, et al.
Publicado: (2018)

Lithocholic Acid Hydroxyamide Destabilizes Cyclin D1 and Induces G(0)/G(1) Arrest by Inhibiting Deubiquitinase USP2a
por: Magiera, Katarzyna, et al.
Publicado: (2017)

Analysis of PD-1 expression in the monocyte subsets from non-septic and septic preterm neonates
por: Zasada, Magdalena, et al.
Publicado: (2017)

Artificial Macrocycles as Potent p53–MDM2 Inhibitors
por: Estrada-Ortiz, Natalia, et al.
Publicado: (2017)

Analysis tools for single-monomer measurements of self-assembly processes
por: Hoyer, Maria, et al.
Publicado: (2022)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes
por: Kuszczak, Bartłomiej, et al.
Publicado: (2023)

Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer
por: Dumitru, Adrian, et al.
Publicado: (2022)

Mechanism of MyD88S mediated signal termination
por: Pustelny, Katarzyna, et al.
Publicado: (2022)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
por: Reddy, Vishwanatha R. A. P., et al.
Publicado: (2019)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_87st590o0tflv3ctf5ern6euoj